DNMUN ... heterogenous neoantigens demands auto? Ref Cancer gene frequencies
Thanks for posting, dnmun. The research clearly points to the obvious -- two critical processes -- thorough interrogation and, by virtue of the vast array of heterogenous antigens ... that autologous therapies will be necessary.
IMO, you cannot YET perform "personalized" cancer therapy (which targets multiple unique neoantigens and the patient's unique immune system TREG profile) and engage logistics to complete complex manufacturing. I say "yet" because I am not aware that any firm has "mastered" knock-in of a patient's TREG control. IMO, they are working on it, but not mastered host vectoring (black box warnings). Do you agree?
Over the next few years we will be scoring improvements in the speed of Ziopharm's TCR-T process (vein to vein time). While Sleeping Beauty enhances safety (by virtue of using the patient's own plasmid as vector), another facet is the simplicity it brings to the TCR-T design (Deniger slide at R&D day).
I suspect that Dr. Drew, in addition to focusing upon improved interrogation to achieve efficacy, he has also been using a portion of the last two years to also shave off TCR-T vein-to-vein time. (Dr. Rosenberg had touted in late 2019 that he had cut six days off of the TCR-T process). What emerges next year on the "speed scorecard" may be kept very quiet by management and only revealed later when we are presenting pivotal results. (I know I would keep a lid on that strategic advantage.)
REFERENCE SINGLE ANTIGEN CAR-T. Four years have passed with three approved CAR-T solutions. Dr. June revealed at our March '21 R&D day that Novartis' CAR-T v-to-v time is "state of the art." Yet Novartis' v-to-v time is 21 days, noted by him as a serious shortcoming impacting patient health and affordability. Again, those CARs are only addressing a single antigen in blood cancers. All the best.